ES2274220T3 - Diagnostico de carcinoma usando polipeptidos raig1. - Google Patents

Diagnostico de carcinoma usando polipeptidos raig1. Download PDF

Info

Publication number
ES2274220T3
ES2274220T3 ES03717443T ES03717443T ES2274220T3 ES 2274220 T3 ES2274220 T3 ES 2274220T3 ES 03717443 T ES03717443 T ES 03717443T ES 03717443 T ES03717443 T ES 03717443T ES 2274220 T3 ES2274220 T3 ES 2274220T3
Authority
ES
Spain
Prior art keywords
raig1
polypeptide
cancer
osteosarcoma
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03717443T
Other languages
English (en)
Spanish (es)
Inventor
J. A. Oxford GlycoSciences TERRETT (UK) Ltd
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB SA
Original Assignee
UCB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0208331.9A external-priority patent/GB0208331D0/en
Priority claimed from GB0221538A external-priority patent/GB0221538D0/en
Application filed by UCB SA filed Critical UCB SA
Application granted granted Critical
Publication of ES2274220T3 publication Critical patent/ES2274220T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES03717443T 2002-04-11 2003-04-10 Diagnostico de carcinoma usando polipeptidos raig1. Expired - Lifetime ES2274220T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0208331 2002-04-11
GBGB0208331.9A GB0208331D0 (en) 2002-04-11 2002-04-11 Proteins
GB0221538A GB0221538D0 (en) 2002-09-17 2002-09-17 A protein involved in carcinoma
GB0221538 2002-09-17

Publications (1)

Publication Number Publication Date
ES2274220T3 true ES2274220T3 (es) 2007-05-16

Family

ID=29252443

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03717443T Expired - Lifetime ES2274220T3 (es) 2002-04-11 2003-04-10 Diagnostico de carcinoma usando polipeptidos raig1.

Country Status (8)

Country Link
US (2) US20050282165A1 (https=)
EP (1) EP1497656B1 (https=)
JP (2) JP2005522226A (https=)
AT (1) ATE347106T1 (https=)
AU (1) AU2003222606A1 (https=)
DE (1) DE60310059T2 (https=)
ES (1) ES2274220T3 (https=)
WO (1) WO2003087832A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1573034A4 (en) * 2002-06-20 2006-06-14 Bristol Myers Squibb Co IDENTIFICATION AND MODULATION OF A G-PROTEIN COUPLED RECEPTOR (GPCR) ASSOCIATED WITH COPD (CHRONIC-OBSTRUCTIVE LUNG DISEASE) AND NF-KB AND E-SELECTIN REGULATION, RAI3
JPWO2021045224A1 (https=) * 2019-09-04 2021-03-11

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068618A1 (en) * 2000-07-26 2003-04-10 Muralidharu Padigaru Novel proteins and nucleic acids encoding same
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
AU2002253878A1 (en) * 2001-01-25 2002-08-06 Gene Logic, Inc. Gene expression profiles in breast tissue
US20030068636A1 (en) * 2001-06-21 2003-04-10 Millennium Pharmaceuticals, Inc. Compositions, kits and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer

Also Published As

Publication number Publication date
EP1497656A2 (en) 2005-01-19
DE60310059D1 (de) 2007-01-11
AU2003222606A1 (en) 2003-10-27
US20090258019A1 (en) 2009-10-15
US20050282165A1 (en) 2005-12-22
JP2010117358A (ja) 2010-05-27
WO2003087832A3 (en) 2004-02-12
ATE347106T1 (de) 2006-12-15
AU2003222606A8 (en) 2003-10-27
EP1497656B1 (en) 2006-11-29
JP2005522226A (ja) 2005-07-28
DE60310059T2 (de) 2007-05-10
WO2003087832A2 (en) 2003-10-23

Similar Documents

Publication Publication Date Title
US8263071B2 (en) Protein involved in ovarian cancer
JP4532273B2 (ja) 癌に関係するタンパク質
US20110150877A1 (en) Ephrin-b receptor protein involved in carcinoma
US20070142276A1 (en) Protein involved in carcinoma
ES2274220T3 (es) Diagnostico de carcinoma usando polipeptidos raig1.
US20070141061A1 (en) Protein involved in carcinoma
US20070269431A1 (en) Protein Involved In Cancer
US20090214540A1 (en) Protein involved in cancer
WO2006000753A2 (en) Use of flj40787, a protein involved in colon, colorectal, ovarian, lung and/or liver cancer
WO2005049066A2 (en) Use of dudulin2 for the treatment or prophylaxis of lung cancer
WO2006003427A1 (en) A protein involved in carcinoma